Andere talen Repligen Corporation

Aandelen

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
165,7 ^USD	-1,31%		+5,48%	-7,86%

08/04	REPLIGEN CORPORATION : RBC Capital Markets herhaalt koopadvies voor het aandeel	ZM
20/03	Transcript : Repligen Corporation Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-20-2024 03:00 PM

Repligen to Report First Quarter 2024 Financial Results	17/04
Repligen : Investor Presentation April 2024 Presentations	02/04
Repligen Appoints Maggie A. Pax to Board of Directors	19/03
Repligen Corporation Appoints Maggie A. Pax as Board of Directors	19/03
Repligen Insider Sold Shares Worth $681,348, According to a Recent SEC Filing	13/03
Repligen Insider Sold Shares Worth $3,298,632, According to a Recent SEC Filing	12/03
Repligen Insider Sold Shares Worth $866,204, According to a Recent SEC Filing	27/02
Aktien Frankfurt Schluss: Dax stabil vor Zahlen des Trendsetters Nvidia	21/02
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday	21/02
Sector Update: Health Care	21/02
Aktien Frankfurt: Dax-Rekordhoch vor Nvidia-Zahlen wieder in Sicht	21/02
Repligen Q4 Adjusted Earnings, Revenue Decline; Issues 2024 Guidance; Shares Fall Premarket	21/02
Sartorius fällt - Ausblick von Repligen enttäuscht	21/02
Repligen: Q4 Earnings Snapshot	21/02
(RGEN) REPLIGEN CORPORATION Expects Fiscal Year 2024 EPS Range $1.42 - $1.49	21/02
Earnings Flash (RGEN) REPLIGEN CORPORATION Reports Q4 Revenue $155.7M, vs. Street Est of $156.3M	21/02
Earnings Flash (RGEN) REPLIGEN CORPORATION Reports Q4 EPS $0.33, vs. Street Est of $0.34	21/02
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results	21/02
Repligen Corporation Provides Earnings Guidance for the Year 2024	21/02
Repligen Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	21/02

Geen resultaten voor deze zoekopdracht